EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impaired monocyte‐derived dendritic cell phenotype in prostate cancer patients: A phenotypic comparison with healthy donors

Parisa Bakhshi, Maryam Nourizadeh, Laleh Sharifi, Mohammad R Nowroozi, Monireh Mohsenzadegan iD, Mohammad M Farajollahi

Cancer Reports · 2024

DOI: 10.1002/cnr2.1996 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Reports, 2024. Verfasst von Parisa Bakhshi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biotechnology, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Vaccines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Iran University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dendritic cells (DCs) play a crucial role in immunity. Research on monocyte‐derived DCs (Mo‐DCs) cancer vaccines is in progress despite limited success in clinical trials. This study focuses on Mo‐DCs generated from prostate cancer (PCA) patients, comparing them with DCs from healthy donors (HD‐DCs).

Methods

Mo‐DCs were isolated from PCA patient samples, and their phenotype was compared to HD‐DCs. Key parameters included monocyte count, CD14 expression, and the levels of maturation markers (HLA‐DR, CD80, CD86) were assessed.

Results

PCA samples exhibited a significantly lower monocyte count and reduced CD14 expression compared to healthy samples (p ⟨ 0.0001). Additionally, PCA‐DCs expressed significantly lower levels of maturation markers, including HLA‐DR, CD80, and CD86, when compared to HD‐DCs ( p = 0.123, p = 0.884, and p = 0.309, respectively).

Conclusion

The limited success of DC vaccines could be attributed to impaired phenotypic characteristics. These observations suggest that suboptimal characteristics of Mo‐DCs generated from cancer patient blood samples might contribute to the limited success of DC vaccines. Consequently, this study underscores the need for alternative strategies to enhance the features of Mo‐DCs for more effective cancer immunotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsVaccinesHumansMaleMonocytesCell DifferentiationDendritic CellsB7-1 AntigenHLA-DR AntigensPhenotype

Stichwörter der Autor:innen

co-stimulatory moleculesdendritic cellsprostate cancer

Substanzen

B7-1 AntigenHLA-DR AntigensVaccines

Autor:innen und Institutionen

  • Department of Medical Biotechnology, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran.
  • Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Monireh Mohsenzadegan

Förderung

  • Iran University of Medical Sciences

Zitieren

APA

Bakhshi, P., Nourizadeh, M., Sharifi, L., Nowroozi, M. R., Mohsenzadegan, M., & Farajollahi, M. M. (2024). Impaired monocyte‐derived dendritic cell phenotype in prostate cancer patients: A phenotypic comparison with healthy donors. Cancer Reports. https://doi.org/10.1002/cnr2.1996

Vancouver

Bakhshi P, Nourizadeh M, Sharifi L, Nowroozi MR, Mohsenzadegan M, Farajollahi MM. Impaired monocyte‐derived dendritic cell phenotype in prostate cancer patients: A phenotypic comparison with healthy donors. Cancer Reports. 2024. doi:10.1002/cnr2.1996

BibTeX
@article{Bakhshi2024,
  author = {Bakhshi, Parisa and Nourizadeh, Maryam and Sharifi, Laleh and Nowroozi, Mohammad R and Mohsenzadegan, Monireh and Farajollahi, Mohammad M},
  title = {Impaired monocyte‐derived dendritic cell phenotype in prostate cancer patients: A phenotypic comparison with healthy donors},
  journal = {Cancer Reports},
  year = {2024},
  doi = {10.1002/cnr2.1996}
}
Kostenlos starten →